Valuation: Kamada Ltd.

Market Cap 1.41B 0 463M 401M 379M 343M 644M 44.41B 649M 4.53B 1.74B 22.52B 1.74B 1.7B 71.82B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.41B 0 463M 401M 379M 343M 644M 44.41B 649M 4.53B 1.74B 22.52B 1.74B 1.7B 71.82B EV / Sales 2026 *
2.33x
EV / Sales 2027 * 2.09x
Free-Float
54.71%
Yield 2026 *
-
Yield 2027 * -
1 day+1.02%
1 week-0.96%
Current month+0.65%
1 month+7.83%
3 months+15.13%
6 months-11.14%
Current year+9.12%
1 week 2,401
Extreme 2401
2,552
1 month 2,200
Extreme 2200
2,578
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 58 01/07/2015
Director of Finance/CFO 56 31/12/2017
Chief Operating Officer 54 01/11/2016
Director TitleAgeSince
Director/Board Member 75 13/12/1990
Chairman 77 07/03/2013
Chairman 55 12/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 Sell

Founder

-175 0.0003%
2/9/26 Exercice

VP Quality

6,937 0.0120%
2/9/26 Exercice

Founder

107,166 0.1857%
Change 5-day change 1-year change 3-year change Capi.($)
+1.02%-0.96%+5.52%+23.67% 463M
-2.47%-4.47%+35.19%-5.99% 77.3B
+0.09%+1.87%-13.62%-34.35% 59.52B
-1.99%+2.45%+502.05%+25.46% 57.4B
-0.56%-1.94%-11.70%+25.63% 47.91B
+0.38%+2.98%+3.33%+154.16% 46.2B
-0.55%+1.73%+50.83%-15.16% 31.94B
-0.37%-2.14%+46.43%+94.63% 24.68B
-0.95%-4.18%-2.23%+136.14% 21.08B
+0.82%-0.05%+58.67%+101.00% 15.65B
Average -0.24%-0.89%+67.45%+50.52% 38.21B
Weighted average by Cap. -0.57%-1.10%+88.88%+35.64%

Financials

2026 *2027 *
Net sales 606M 0 199M 172M 163M 148M 277M 19.1B 279M 1.95B 749M 9.69B 748M 731M 30.89B 673M 0 221M 192M 181M 164M 308M 21.23B 310M 2.16B 832M 10.76B 831M 813M 34.32B
Net income 84.8M 0 27.87M 24.14M 22.83M 20.67M 38.79M 2.67B 39.08M 272M 105M 1.36B 105M 102M 4.32B 104M 0 34.22M 29.64M 28.03M 25.38M 47.63M 3.28B 47.99M 334M 129M 1.66B 129M 126M 5.31B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
16/09/26 ILA 2,466.00 +1.02% 10,823
15/09/26 ILA 2,441.00 -2.55% 101,220
14/09/26 ILA 2,505.00 +2.16% 275,975
10/09/26 ILA 2,452.00 -1.53% 69,336
09/09/26 ILA 2,490.00 +0.08% 130,011
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!